# US 2025/0152653 A1 · Ashwagandha extracts and formulations thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152653 A1
- Document ID: US20250152653A1
- Status: Published application
- Kind: A1
- Application number: 18/730,195
- Filed: 2023-01-20
- Published: 2025-05-15
- Earliest claimed: 2022-01-21
- Assignees: ReBalance Health, Inc.
- Applicants: ReBalance Health, Inc.
- Inventors: Justin HAI; Russell GLENN
- Web page: https://patentgrep.com/patent/US20250152653A1

## CPC

- A61K 36/481: Astragalus (milkvetch)
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 36/068: Cordyceps
- A61K 36/258: Panax (ginseng)
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Certain embodiments provide a composition comprising an organic extract and one or more excipients. For instance, certain compositions include an ashwagandha extract, a chelating agent, and an agent that enhances the delivery of one or more ingredients of the compositions. Non-limiting example compositions include ashwagandha extract, ethylenediaminetetraacetic acid (EDTA), and extracts of Panax notoginseng and Astragalus membranaceus. The compositions may further include one or more ingredients such as organic extract or powder (e.g., from herbs, roots, plants); vitamins; minerals; amino acids; adaptogens; and combinations of two or more thereof. Described herein are ashwagandha extract compositions formulated for oral delivery for use in a variety of applications, such as use against conditions such as low energy, anxiety, the inability to fall asleep, or a combination of one or more thereof.

## Claims

### Claim 1

A composition comprising an ashwagandha extract, a first excipient comprising an extract of Astragalus membranaceus and an extract of Panax notoginseng, and a second excipient comprising a chelating agent.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the ashwagandha extract is present in the composition at about 20% to about 40% (w/w) or about 40% to about 60% (w/w); and/or wherein about 100 mg to about 400 mg or about 50 mg to about 250 mg of the ashwagandha extract is present in the composition.

### Claim 3 (depends on 1, 2)

The composition of claim 1 or claim 2, wherein the first excipient is present in the composition at about 1% to about 19% (w/w), about 5% to about 15% (w/w), or about 1% to about 10% (w/w); and/or wherein the composition comprises about 25 mg to about 75 mg, about 10 mg to about 50 mg, or about 10 mg to about 40 mg of the first excipient.

### Claim 4 (depends on 1, 2)

The composition of claim 1 or claim 2, wherein the second excipient is present in the composition at about 1% to about 19% (w/w), about 5% to about 15% (w/w), or about 1% to about 10% (w/w); and/or wherein the composition comprises about 25 mg to about 75 mg or about 10 mg to about 50 mg of the second excipient.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the second excipient is present in the composition at about 1% to about 19% (w/w), about 5% to about 15% (w/w), or about 1% to about 10% (w/w); and/or wherein the composition comprises about 25 mg to about 75 mg or about 10 mg to about 50 mg of the second excipient.

### Claim 6 (depends on 1, 2)

The composition of claim 1 or claim 2, wherein the chelating agent comprises ethylenediaminetetraacetic acid (EDTA), deferoxamine, deferasirox, deferiprone, penicillamine, trientine, dimercaprol, ethylenediamine, porphine, heme, sodium gluconate, tetrasodium glutamate diacetate, phytic acid, or a combination of two or more thereof.

### Claim 7 (depends on 3, 4, 5)

The composition of any one of claims 3-5, wherein the chelating agent comprises ethylenediaminetetraacetic acid (EDTA), deferoxamine, deferasirox, deferiprone, penicillamine, trientine, dimercaprol, ethylenediamine, porphine, heme, sodium gluconate, tetrasodium glutamate diacetate, phytic acid, or a combination of two or more thereof.

### Claim 8 (depends on 1, 2)

The composition of claim 1 or claim 2, comprising (a) a melatonin, optionally present in the composition at about 0.01% (w/w) to about 2% (w/w), and optionally about 0.01 mg to about 5 mg of the melatonin is present in the composition; (b) a phosphatidylserine, optionally present in the composition at about 5% to about 25% (w/w) or about 0.5% to about 10% (w/w), and optionally about 25 mg to about 225 mg or about 1 mg to about 25 mg of the phosphatidylserine is present in the composition; (c) a supplemental mineral, optionally present in the composition at about 0.5% to about 11%, and optionally about 5 mg to about 90 mg is present in the composition; (d) a compound derived from a magnolia tree, optionally present in the composition at about 0.5% to about 11% (w/w), and optionally about 10 mg to about 90 mg of the compound derived from a magnolia tree is present in the composition; (e) a ginger, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the ginger is present in the composition; (f) a horny goat weed, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the horny goat weed is present in the composition; (g) a sclareolides, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the sclareolides is present in the composition; (h) a diindolylmethane (DIM), optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the diindolylmethane (DIM) is present in the composition; (i) a zinc, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 20 mg of the zinc is present in the composition; (j) a an extraction from the aerial parts of oat plants, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the an extraction from the aerial parts of oat plants is present in the composition; (k) a maca, optionally present in the composition at about 5% (w/w) to about 35% (w/w), and optionally about 100 mg to about 400 mg of the maca is present in the composition; (l) a Eurycoma longifolia, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the Eurycoma longifolia is present in the composition; (m) a fenugreek seed extract, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the fenugreek seed extract is present in the composition; (n) a Tribulus terrestris, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the Tribulus terrestris is present in the composition; (o) a tea extract, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6%, and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the tea extract is present in the composition; (p) a vitamin, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% (w/w) to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the vitamin is present in the composition; (q) a nitric oxide source, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the nitric oxide source is present in the composition; (r) an amino acid, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the amino acid is present in the composition; (s) a Panax ginseng, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the Panax ginseng is present in the composition; (t) a Bacopa monieri, optionally present in the composition at about 0.5% (w/w) to about 1.6% (w/w), and optionally about 4.5 mg to about 15 mg of the Bacopa monieri is present in the composition; (u) a L-theanine, optionally present in the composition at about 0.1% (w/w) to about 8% (w/w), and optionally about 4.5 mg to about 15 mg of the L-theanine is present in the composition; (v) a L-tryptophan, optionally present in the composition at about 0.1% (w/w) to about 7% (w/w), and optionally about 2.5 mg to about 12.5 mg of the L-tryptophan is present in the composition; (w) a reishi mushroom, optionally present in the composition at about 1% (w/w) to about 3% (w/w), and optionally about 0.5 mg to about 10 mg of the reishi mushroom is present in the composition; (x) a cordyceps species, optionally present in the composition at about 5% to about 35% (w/w) or about 0.1% to about 1.5% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 100 mg to about 300 mg or about 0.5 mg to about 15 mg or about 4.5 mg to about 15 mg of the cordyceps species is present in the composition; or (y) a combination of two or more selected from (a)-(x).

### Claim 9 (depends on 3, 4, 5, 6, 7)

The composition of any one of claims 3-7, comprising: (a) a melatonin, optionally present in the composition at about 0.01% (w/w) to about 2% (w/w), and optionally about 0.01 mg to about 5 mg of the melatonin is present in the composition; (b) a phosphatidylserine, optionally present in the composition at about 5% to about 25% (w/w) or about 0.5% to about 10% (w/w), and optionally about 25 mg to about 225 mg or about 1 mg to about 25 mg of the phosphatidylserine is present in the composition; (c) a supplemental mineral, optionally present in the composition at about 0.5% to about 11%, and optionally about 5 mg to about 90 mg is present in the composition; (d) a compound derived from a magnolia tree, optionally present in the composition at about 0.5% to about 11% (w/w), and optionally about 10 mg to about 90 mg of the compound derived from a magnolia tree is present in the composition; (e) a ginger, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the ginger is present in the composition; (f) a horny goat weed, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the horny goat weed is present in the composition; (g) a sclareolides, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the sclareolides is present in the composition; (h) a diindolylmethane (DIM), optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the diindolylmethane (DIM) is present in the composition; (i) a zinc, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 20 mg of the zinc is present in the composition; (j) a an extraction from the aerial parts of oat plants, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the an extraction from the aerial parts of oat plants is present in the composition; (k) a maca, optionally present in the composition at about 5% (w/w) to about 35% (w/w), and optionally about 100 mg to about 400 mg of the maca is present in the composition; (l) a Eurycoma longifolia, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the Eurycoma longifolia is present in the composition; (m) a fenugreek seed extract, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the fenugreek seed extract is present in the composition; (n) a Tribulus terrestris, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the Tribulus terrestris is present in the composition; (o) a tea extract, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6%, and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the tea extract is present in the composition; (p) a vitamin, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% (w/w) to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the vitamin is present in the composition; (q) a nitric oxide source, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the nitric oxide source is present in the composition; (r) an amino acid, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the amino acid is present in the composition; (s) a Panax ginseng, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the Panax ginseng is present in the composition; (t) a Bacopa monieri, optionally present in the composition at about 0.5% (w/w) to about 1.6% (w/w), and optionally about 4.5 mg to about 15 mg of the Bacopa monieri is present in the composition; (u) a L-theanine, optionally present in the composition at about 0.1% (w/w) to about 8% (w/w), and optionally about 4.5 mg to about 15 mg of the L-theanine is present in the composition; (v) a L-tryptophan, optionally present in the composition at about 0.1% (w/w) to about 7% (w/w), and optionally about 2.5 mg to about 12.5 mg of the L-tryptophan is present in the composition; (w) a reishi mushroom, optionally present in the composition at about 1% (w/w) to about 3% (w/w), and optionally about 0.5 mg to about 10 mg of the reishi mushroom is present in the composition; (x) a cordyceps species, optionally present in the composition at about 5% to about 35% (w/w) or about 0.1% to about 1.5% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 100 mg to about 300 mg or about 0.5 mg to about 15 mg or about 4.5 mg to about 15 mg of the cordyceps species is present in the composition; or (y) a combination of two or more selected from (a)-(x).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The composition of any one of claims 1-9, comprising a flavoring agent, optionally present in the composition at about 1% to about 15% (w/w), and optionally about 4 mg to about 800 mg of the flavoring agent is present in the composition.

### Claim 11

A composition comprising an ashwagandha extract and an excipient comprising an extract of Astragalus membranaceus and an extract of Panax notoginseng.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the ashwagandha extract is present in the composition at about 20% to about 40% (w/w) or about 40% to about 60% (w/w); and/or wherein about 100 mg to about 400 mg or about 50 mg to about 250 mg of the ashwagandha extract is present in the composition.

### Claim 13 (depends on 11, 12)

The composition of claim 11 or claim 12, wherein the excipient is present in the composition at about 1% to about 19% (w/w), about 5% to about 15% (w/w), or about 1% to about 10% (w/w); and/or wherein the composition comprises about 25 mg to about 75 mg, about 10 mg to about 50 mg, or about 10 mg to about 40 mg of the first excipient.

### Claim 14 (depends on 11, 12, 13)

The composition of any one of claims 11-13, comprising (a) a cordyceps species, optionally present in the composition at about 5% to about 35% (w/w) or about 0.1% to about 1.5% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 100 mg to about 300 mg or about 0.5 mg to about 15 mg or about 4.5 mg to about 15 mg of the cordyceps species is present in the composition; (b) a phosphatidylserine, optionally present in the composition at about 5% to about 25% (w/w) or about 0.5% to about 10% (w/w), and optionally about 25 mg to about 225 mg or about 1 mg to about 25 mg of the phosphatidylserine is present in the composition; (c) a supplemental mineral, optionally present in the composition at about 0.5% to about 11%, and optionally about 5 mg to about 90 mg is present in the composition; (d) a compound derived from a magnolia tree, optionally present in the composition at about 0.5% to about 11% (w/w), and optionally about 10 mg to about 90 mg of the compound derived from a magnolia tree is present in the composition; (e) a ginger, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the ginger is present in the composition; (f) a horny goat weed, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the horny goat weed is present in the composition; (g) a sclareolides, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the sclareolides is present in the composition; (h) a diindolylmethane (DIM), optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the diindolylmethane (DIM) is present in the composition; (i) a zinc, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 20 mg of the zinc is present in the composition; (j) a an extraction from the aerial parts of oat plants, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the an extraction from the aerial parts of oat plants is present in the composition; (k) a maca, optionally present in the composition at about 5% (w/w) to about 35% (w/w), and optionally about 100 mg to about 400 mg of the maca is present in the composition; (l) a Eurycoma longifolia, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the Eurycoma longifolia is present in the composition; (m) a fenugreek seed extract, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the fenugreek seed extract is present in the composition; (n) a Tribulus terrestris, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the Tribulus terrestris is present in the composition; (o) a tea extract, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6%, and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the tea extract is present in the composition; (p) a vitamin, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% (w/w) to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the vitamin is present in the composition; (q) a nitric oxide source, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the nitric oxide source is present in the composition; (r) an amino acid, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the amino acid is present in the composition; (s) a Panax ginseng, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the Panax ginseng is present in the composition; (t) a Bacopa monieri, optionally present in the composition at about 0.5% (w/w) to about 1.6% (w/w), and optionally about 4.5 mg to about 15 mg of the Bacopa monieri is present in the composition; (u) a L-theanine, optionally present in the composition at about 0.1% (w/w) to about 8% (w/w), and optionally about 4.5 mg to about 15 mg of the L-theanine is present in the composition; (v) a L-tryptophan, optionally present in the composition at about 0.1% (w/w) to about 7% (w/w), and optionally about 2.5 mg to about 12.5 mg of the L-tryptophan is present in the composition; (w) a reishi mushroom, optionally present in the composition at about 1% (w/w) to about 3% (w/w), and optionally about 0.5 mg to about 10 mg of the reishi mushroom is present in the composition; (x) a melatonin, optionally present in the composition at about 0.01% (w/w) to about 2% (w/w), and optionally about 0.01 mg to about 5 mg of the melatonin is present in the composition; or (y) a combination of two or more selected from (a)-(x).

### Claim 15 (depends on 11, 12, 13, 14)

The composition of any one of claims 11-14, comprising a flavoring agent, optionally present in the composition at about 1% to about 15% (w/w), and optionally about 4 mg to about 800 mg of the flavoring agent is present in the composition.

### Claim 16

A composition comprising an ashwagandha extract and an excipient comprising a chelating agent.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the ashwagandha extract is present in the composition at about 20% to about 40% (w/w) or about 40% to about 60% (w/w); and/or wherein about 100 mg to about 400 mg or about 50 mg to about 250 mg of the ashwagandha extract is present in the composition.

### Claim 18 (depends on 16, 17)

The composition of claim 16 or claim 17, wherein the excipient is present in the composition at about 1% to about 19% (w/w), about 5% to about 15% (w/w), or about 1% to about 10% (w/w); and/or wherein the composition comprises about 25 mg to about 75 mg or about 10 mg to about 50 mg of the second excipient.

### Claim 19 (depends on 16, 17, 18)

The composition of any one of claims 16-18, wherein the chelating agent comprises ethylenediaminetetraacetic acid (EDTA), deferoxamine, deferasirox, deferiprone, penicillamine, trientine, dimercaprol, ethylenediamine, porphine, heme, sodium gluconate, tetrasodium glutamate diacetate, phytic acid, or a combination of two or more thereof.

### Claim 20 (depends on 16, 17, 18, 19)

The composition of any one of claims 16-19, comprising (a) a cordyceps species, optionally present in the composition at about 5% to about 35% (w/w) or about 0.1% to about 1.5% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 100 mg to about 300 mg or about 0.5 mg to about 15 mg or about 4.5 mg to about 15 mg of the cordyceps species is present in the composition; (b) a phosphatidylserine, optionally present in the composition at about 5% to about 25% (w/w) or about 0.5% to about 10% (w/w), and optionally about 25 mg to about 225 mg or about 1 mg to about 25 mg of the phosphatidylserine is present in the composition; (c) a supplemental mineral, optionally present in the composition at about 0.5% to about 11%, and optionally about 5 mg to about 90 mg is present in the composition; (d) a compound derived from a magnolia tree, optionally present in the composition at about 0.5% to about 11% (w/w), and optionally about 10 mg to about 90 mg of the compound derived from a magnolia tree is present in the composition; (e) a ginger, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the ginger is present in the composition; (f) a horny goat weed, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the horny goat weed is present in the composition; (g) a sclareolides, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the sclareolides is present in the composition; (h) a diindolylmethane (DIM), optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the diindolylmethane (DIM) is present in the composition; (i) a zinc, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 20 mg of the zinc is present in the composition; (j) a an extraction from the aerial parts of oat plants, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the an extraction from the aerial parts of oat plants is present in the composition; (k) a maca, optionally present in the composition at about 5% (w/w) to about 35% (w/w), and optionally about 100 mg to about 400 mg of the maca is present in the composition; (l) a Eurycoma longifolia, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the Eurycoma longifolia is present in the composition; (m) a fenugreek seed extract, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the fenugreek seed extract is present in the composition; (n) a Tribulus terrestris, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the Tribulus terrestris is present in the composition; (o) a tea extract, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6%, and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the tea extract is present in the composition; (p) a vitamin, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% (w/w) to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the vitamin is present in the composition; (q) a nitric oxide source, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the nitric oxide source is present in the composition; (r) an amino acid, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the amino acid is present in the composition; (s) a Panax ginseng, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the Panax ginseng is present in the composition; (t) a Bacopa monieri, optionally present in the composition at about 0.5% (w/w) to about 1.6% (w/w), and optionally about 4.5 mg to about 15 mg of the Bacopa monieri is present in the composition; (u) a L-theanine, optionally present in the composition at about 0.1% (w/w) to about 8% (w/w), and optionally about 4.5 mg to about 15 mg of the L-theanine is present in the composition; (v) a L-tryptophan, optionally present in the composition at about 0.1% (w/w) to about 7% (w/w), and optionally about 2.5 mg to about 12.5 mg of the L-tryptophan is present in the composition; (w) a reishi mushroom, optionally present in the composition at about 1% (w/w) to about 3% (w/w), and optionally about 0.5 mg to about 10 mg of the reishi mushroom is present in the composition; (x) a melatonin, optionally present in the composition at about 0.01% (w/w) to about 2% (w/w), and optionally about 0.01 mg to about 5 mg of the melatonin is present in the composition; or (y) a combination of two or more selected from (a)-(x).

### Claim 21 (depends on 16, 17, 18, 19, 20)

The composition of any one of claims 16-20, comprising a flavoring agent, optionally present in the composition at about 1% to about 15% (w/w), and optionally about 4 mg to about 800 mg of the flavoring agent is present in the composition.

### Claim 22

A composition comprising a first excipient comprising an extract of Astragalus membranaceus and an extract of Panax notoginseng, and a second excipient comprising a chelating agent.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the first excipient is present in the composition at about 1% to about 19% (w/w), about 5% to about 15% (w/w), or about 1% to about 10% (w/w); and/or wherein the composition comprises about 25 mg to about 75 mg, about 10 mg to about 50 mg, or about 10 mg to about 40 mg of the first excipient.

### Claim 24 (depends on 22, 23)

The composition of claim 22 or claim 23, wherein the second excipient is present in the composition at about 1% to about 19% (w/w), about 5% to about 15% (w/w), or about 1% to about 10% (w/w); and/or wherein the composition comprises about 25 mg to about 75 mg or about 10 mg to about 50 mg of the second excipient.

### Claim 25 (depends on 22, 23, 24)

The composition of any one of claims 22-24, wherein the chelating agent comprises ethylenediaminetetraacetic acid (EDTA), deferoxamine, deferasirox, deferiprone, penicillamine, trientine, dimercaprol, ethylenediamine, porphine, heme, sodium gluconate, tetrasodium glutamate diacetate, phytic acid, or a combination of two or more thereof.

### Claim 26 (depends on 22, 23, 24, 25)

The composition of any one of claims 22-25, comprising (a) a cordyceps species, optionally present in the composition at about 5% to about 35% (w/w) or about 0.1% to about 1.5% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 100 mg to about 300 mg or about 0.5 mg to about 15 mg or about 4.5 mg to about 15 mg of the cordyceps species is present in the composition; (b) a phosphatidylserine, optionally present in the composition at about 5% to about 25% (w/w) or about 0.5% to about 10% (w/w), and optionally about 25 mg to about 225 mg or about 1 mg to about 25 mg of the phosphatidylserine is present in the composition; (c) a supplemental mineral, optionally present in the composition at about 0.5% to about 11%, and optionally about 5 mg to about 90 mg is present in the composition; (d) a compound derived from a magnolia tree, optionally present in the composition at about 0.5% to about 11% (w/w), and optionally about 10 mg to about 90 mg of the compound derived from a magnolia tree is present in the composition; (e) a ginger, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the ginger is present in the composition; (f) a horny goat weed, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the horny goat weed is present in the composition; (g) a sclareolides, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the sclareolides is present in the composition; (h) a diindolylmethane (DIM), optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the diindolylmethane (DIM) is present in the composition; (i) a zinc, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 20 mg of the zinc is present in the composition; (j) a an extraction from the aerial parts of oat plants, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the an extraction from the aerial parts of oat plants is present in the composition; (k) a maca, optionally present in the composition at about 5% (w/w) to about 35% (w/w), and optionally about 100 mg to about 400 mg of the maca is present in the composition; (l) a Eurycoma longifolia, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the Eurycoma longifolia is present in the composition; (m) a fenugreek seed extract, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the fenugreek seed extract is present in the composition; (n) a Tribulus terrestris, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the Tribulus terrestris is present in the composition; (o) a tea extract, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6%, and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the tea extract is present in the composition; (p) a vitamin, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% (w/w) to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the vitamin is present in the composition; (q) a nitric oxide source, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the nitric oxide source is present in the composition; (r) an amino acid, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the amino acid is present in the composition; (s) a Panax ginseng, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the Panax ginseng is present in the composition; (t) a Bacopa monieri, optionally present in the composition at about 0.5% (w/w) to about 1.6% (w/w), and optionally about 4.5 mg to about 15 mg of the Bacopa monieri is present in the composition; (u) a L-theanine, optionally present in the composition at about 0.1% (w/w) to about 8% (w/w), and optionally about 4.5 mg to about 15 mg of the L-theanine is present in the composition; (v) a L-tryptophan, optionally present in the composition at about 0.1% (w/w) to about 7% (w/w), and optionally about 2.5 mg to about 12.5 mg of the L-tryptophan is present in the composition; (w) a reishi mushroom, optionally present in the composition at about 1% (w/w) to about 3% (w/w), and optionally about 0.5 mg to about 10 mg of the reishi mushroom is present in the composition; (x) a melatonin, optionally present in the composition at about 0.01% (w/w) to about 2% (w/w), and optionally about 0.01 mg to about 5 mg of the melatonin is present in the composition; or (y) a combination of two or more selected from (a)-(x).

### Claim 27 (depends on 22, 23, 24, 25, 26)

The composition of any one of claims 22-26, comprising a flavoring agent, optionally present in the composition at about 1% to about 15% (w/w), and optionally about 4 mg to about 800 mg of the flavoring agent is present in the composition.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The composition of any one of claims 1-27, (a) formulated in a tablet; (b) formulated in an oral dissolving tablet, optionally wherein the composition disintegrates in water in less than about 10 minutes, 9 minutes, 8 minutes, 7 minutes, 6 minutes, 5 minutes, 4 minutes, 3 minutes, 2 minutes, or 1 minute; (c) wherein the composition is prepared in a process comprising lyophilization; (d) wherein the composition is prepared in a unit having a weight of about 350 mg to about 1350 mg; or (e) a combination of two or more of (a) to (d).

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method of modulating cortisol in a person, the method comprising taking a composition of any one of claims 1-28; optionally (a) wherein the delivery is oral; (b) wherein the composition increases energy, as compared to the person prior to taking the composition; (c) wherein the composition facilitates relaxation, as compared to the person prior to taking the composition; (d) wherein the composition improves sleep, as compared to the person prior to taking the composition; (e) wherein the composition is taken a regimen comprises two or more units, further optionally wherein each unit is taken daily or twice daily; further optionally wherein the regimen comprises taking the composition once daily for a week; (f) wherein the person is a female and the composition reduces a symptom of perimenopause or menopause in the female, as compared to the female prior to taking the composition; or (g) a combination of two or more of (a) to (f).

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method of improving the health of a person, the method comprising taking a composition of any one of claims 1-28; optionally (a) wherein the delivery is oral; (b) wherein the composition increases energy, as compared to the person prior to taking the composition; (c) wherein the composition facilitates relaxation, as compared to the person prior to taking the composition; (d) wherein the composition improves sleep, as compared to the person prior to taking the composition; (e) wherein the composition is taken a regimen comprises two or more units, further optionally wherein each unit is taken daily or twice daily; further optionally wherein the regimen comprises taking the composition once daily for a week; (f) wherein the person is a female and the composition reduces a symptom of perimenopause or menopause in the female, as compared to the female prior to taking the composition; or (g) a combination of two or more of (a) to (f).

### Claim 31

A method of enhancing oral delivery of a composition comprising an ashwagandha extract, the method comprising combining with the ashwagandha extract (a) a first excipient comprising an extract of Astragalus membranaceus and an extract of Panax notoginseng, and/or (b) a second excipient comprising a chelating agent.

### Claim 32

A method of enhancing oral delivery of an agent, the method comprising combining with the agent (a) a first excipient comprising an extract of Astragalus membranaceus and an extract of Panax notoginseng, and/or (b) a second excipient comprising a chelating agent; wherein the agent comprises: (a) a cordyceps species, optionally present in the composition at about 5% to about 35% (w/w) or about 0.1% to about 1.5% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 100 mg to about 300 mg or about 0.5 mg to about 15 mg or about 4.5 mg to about 15 mg of the cordyceps species is present in the composition; (b) a phosphatidylserine, optionally present in the composition at about 5% to about 25% (w/w) or about 0.5% to about 10% (w/w), and optionally about 25 mg to about 225 mg or about 1 mg to about 25 mg of the phosphatidylserine is present in the composition; (c) a supplemental mineral, optionally present in the composition at about 0.5% to about 11%, and optionally about 5 mg to about 90 mg is present in the composition; (d) a compound derived from a magnolia tree, optionally present in the composition at about 0.5% to about 11% (w/w), and optionally about 10 mg to about 90 mg of the compound derived from a magnolia tree is present in the composition; (e) a ginger, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the ginger is present in the composition; (f) a horny goat weed, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the horny goat weed is present in the composition; (g) a sclareolides, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the sclareolides is present in the composition; (h) a diindolylmethane (DIM), optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the diindolylmethane (DIM) is present in the composition; (i) a zinc, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 20 mg of the zinc is present in the composition; (j) a an extraction from the aerial parts of oat plants, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the an extraction from the aerial parts of oat plants is present in the composition; (k) a maca, optionally present in the composition at about 5% (w/w) to about 35% (w/w), and optionally about 100 mg to about 400 mg of the maca is present in the composition; (l) a Eurycoma longifolia, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the Eurycoma longifolia is present in the composition; (m) a fenugreek seed extract, optionally present in the composition at about 5% (w/w) to about 25% (w/w), and optionally about 25 mg to about 275 mg of the fenugreek seed extract is present in the composition; (n) a Tribulus terrestris, optionally present in the composition at about 0.1% (w/w) to about 2.5% (w/w), and optionally about 1 mg to about 25 mg of the Tribulus terrestris is present in the composition; (o) a tea extract, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6%, and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the tea extract is present in the composition; (p) a vitamin, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% (w/w) to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the vitamin is present in the composition; (q) a nitric oxide source, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w) or about 0.8% to about 1.6% (w/w), and optionally about 0.5 mg to about 10 mg or about 4.5 mg to about 15 mg of the nitric oxide source is present in the composition; (r) an amino acid, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the amino acid is present in the composition; (s) a Panax ginseng, optionally present in the composition at about 0.1% (w/w) to about 1% (w/w), and optionally about 0.5 mg to about 10 mg of the Panax ginseng is present in the composition; (t) a Bacopa monieri, optionally present in the composition at about 0.5% (w/w) to about 1.6% (w/w), and optionally about 4.5 mg to about 15 mg of the Bacopa monieri is present in the composition; (u) a L-theanine, optionally present in the composition at about 0.1% (w/w) to about 8% (w/w), and optionally about 4.5 mg to about 15 mg of the L-theanine is present in the composition; (v) a L-tryptophan, optionally present in the composition at about 0.1% (w/w) to about 7% (w/w), and optionally about 2.5 mg to about 12.5 mg of the L-tryptophan is present in the composition; (w) a reishi mushroom, optionally present in the composition at about 1% (w/w) to about 3% (w/w), and optionally about 0.5 mg to about 10 mg of the reishi mushroom is present in the composition; (x) a melatonin, optionally present in the composition at about 0.01% (w/w) to about 2% (w/w), and optionally about 0.01 mg to about 5 mg of the melatonin is present in the composition; or (y) a combination of two or more selected from (a)-(x).

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31)

The method of claim 30 or 31, wherein the composition is selected from the composition of any one of claims 1-28.
